deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT03161431

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Sponsor: Dana-Farber Cancer Institute

Conditions Melanoma Stage III Melanoma Stage IV
Interventions Pembrolizumab SX-682
Updated 19 times since 2017 Last updated: Dec 19, 2025 Started: Jun 12, 2019 Primary completion: Aug 31, 2026 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Melanoma Stage III and Melanoma Stage IV, this trial is ongoing. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 19 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Oct 2020 · 12 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Mar 2023 · 12 months · monthly snapshot~Mar 2023 – ~Jan 2024 · 10 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Jan 2026 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jan 2024 — Jun 2024 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Mar 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  2. Mar 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  7. Oct 2019 — Oct 2020 [monthly]

    Recruiting PHASE1

  8. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  9. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  10. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Dec 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE1

  12. Oct 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1

  13. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1

  14. Jun 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • Massachusetts General Hospital
  • Mayo Clinic
  • National Cancer Institute (NCI)
  • Syntrix Biosystems, Inc.
  • University of Miami
  • University of Rochester
Data source: Syntrix Biosystems, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations